Chinese innovative drugs developer Allist Pharmaceuticals has raised RMB1.18 billion ($170.75 million) in a new funding round led by healthcare-focused private equity firm Shiyu Capital, according to an announcement.
Loyal Valley Capital and Suzhou Industrial Park Bioventure Investment also participated in the round.
